Literature DB >> 8338770

Normal individuals with high Hb A2 levels.

D Gasperini1, A Cao, L Paderi, S Barella, E Paglietti, L Perseu, D Loi, R Galanello.   

Abstract

Increased haemoglobin (Hb) A2 levels associated with reduced mean corpuscular volume (MCV) and Hb content per cell (MCH) are the most typical features of heterozygous beta thalassaemia. However, double heterozygotes for alpha and beta thalassaemia may have normal MCV and MCH but Hb A2 always in the carrier range. In this report we describe two Sardinian families who have increased Hb A2 levels, normal red blood cell indices and normal globin chain synthesis and in whom DNA sequence analysis of beta and delta globin genes did not reveal any abnormality. Our findings demonstrate the existence of a genetic trait not resulting from a defect of the beta globin gene cluster, transmitted in a dominant manner and manifested as isolated increase of Hb A2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8338770     DOI: 10.1111/j.1365-2141.1993.tb03042.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Implications of increased haemoglobin A2 values in HIV positive women in the antenatal clinic.

Authors:  J Howard; J S Henthorn; S Murphy; S C Davies
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 2.  The prevention of thalassemia.

Authors:  Antonio Cao; Yuet Wai Kan
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

3.  Etiology of anemia of blood donor candidates deferred by hematologic screening.

Authors:  Michel Alves da Silva; Renata Andréia Volpe de Souza; Aline Meneses Carlos; Sheila Soares; Helio Moraes-Souza; Gilberto de Araujo Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

4.  β-Thalassemia pathogenic variants in a cohort of children from the East African coast.

Authors:  Alexander W Macharia; George Mochamah; Sophie Uyoga; Carolyne M Ndila; Gideon Nyutu; Metrine Tendwa; Emily Nyatichi; Johnstone Makale; Russell E Ware; Thomas N Williams
Journal:  Mol Genet Genomic Med       Date:  2020-05-11       Impact factor: 2.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.